Sangui Biotech Valuation
| SGBI Stock | USD 0 0.00 0.00% |
Sangui Biotech seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Sangui Biotech Inter from inspecting the company fundamentals such as Return On Asset of -0.64, shares owned by insiders of 13.03 %, and Current Valuation of 1.68 M as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sangui Biotech's price fluctuation is very steady at this time. Calculation of the real value of Sangui Biotech Inter is based on 3 months time horizon. Increasing Sangui Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Sangui Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sangui Pink Sheet. However, Sangui Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0015 | Real 0.00126 | Hype 0.0015 | Naive 0.0015 |
The intrinsic value of Sangui Biotech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Sangui Biotech's stock price.
Estimating the potential upside or downside of Sangui Biotech International helps investors to forecast how Sangui pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sangui Biotech more accurately as focusing exclusively on Sangui Biotech's fundamentals will not take into account other important factors: Sangui Biotech Total Value Analysis
Sangui Biotech International is at this time forecasted to have valuation of 1.68 M with market capitalization of 902.58 K, debt of 48.9 K, and cash on hands of 30.47 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Sangui Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.68 M | 902.58 K | 48.9 K | 30.47 K |
Sangui Biotech Investor Information
About 13.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Sangui Biotech International is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Sangui Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sangui Biotech has an asset utilization ratio of 52.9 percent. This signifies that the Company is making $0.53 for each dollar of assets. An increasing asset utilization means that Sangui Biotech International is more efficient with each dollar of assets it utilizes for everyday operations.Sangui Biotech Ownership Allocation
Sangui Biotech Inter shows a total of 209.9 Million outstanding shares. Sangui Biotech Inter has 13.03 % of its outstanding shares held by insiders and 0.0 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Sangui Biotech Profitability Analysis
The company reported the previous year's revenue of 69.19 K. Net Loss for the year was (63.34 K) with profit before overhead, payroll, taxes, and interest of 69.19 K.About Sangui Biotech Valuation
An absolute valuation paradigm, as applied to Sangui Pink Sheet, attempts to find the value of Sangui Biotech Inter based on its fundamental and basic technical indicators. By analyzing Sangui Biotech's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Sangui Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Sangui Biotech. We calculate exposure to Sangui Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sangui Biotech's related companies.Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany. Sangui Biotech is traded on OTC Exchange in the United States.
8 Steps to conduct Sangui Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Sangui Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Sangui Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Sangui Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Sangui Biotech's revenue streams: Identify Sangui Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Sangui Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Sangui Biotech's growth potential: Evaluate Sangui Biotech's management, business model, and growth potential.
- Determine Sangui Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Sangui Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Sangui Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 204.2 M | |
| Retained Earnings | -38 M |
Complementary Tools for Sangui Pink Sheet analysis
When running Sangui Biotech's price analysis, check to measure Sangui Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangui Biotech is operating at the current time. Most of Sangui Biotech's value examination focuses on studying past and present price action to predict the probability of Sangui Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangui Biotech's price. Additionally, you may evaluate how the addition of Sangui Biotech to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |